Join the club for FREE to access the whole archive and other member benefits.

SIRT6 variant plays a major role in preventing the aging process

Novel gene therapies to prevent the accelerated aging process

17-Aug-2021

Key points from article :

Genflow Biosciences is on a mission to develop gene therapies designed to slow the aging process.

Developing therapies that deliver a variant of the sirtuin 6 (SIRT6) gene found in centenarians.

It has a pipeline of compounds for human indications, idiopathic pulmonary fibrosis (IPF) and Werner’s syndrome.

veteran Leire says "It’s a fantastic tool but, it boxes companies into a senescence company, a mitochondria company, or a stem cell company".

SIRT6 is one of many genes that repair our DNA, from a therapeutic perspective.

It’s more interesting than others because DNA repair seems to be its only function.

SIRT6 can be easily delivered into cells, so it’s possible to use it as a gene therapy target.

Gene therapy was costlier before but today there are companies developing clinical trials with AAVs.

Leire says "Yes, we will have a trial in Werner’s syndrome, but we consider that a door opener to having a true aging indication".

Genflow’s preclinical work to continue over the next 12–18 months.

Mentioned in this article:

Click on resource name for more details.

Eric Leire

CEO of Genflow Biosciences and Executive Chairman of Immunethep

Genflow Biosciences

Developing medicines that potentially halt, slow or reverse the aging process

Jim Mellon

British entrepreneur, author and philanthropist with interests across a number of industries

University of Rochester

Private research university that grants undergraduate and graduate degrees, including doctoral and professional degrees

Vera Gorbunova

Co-director Rochester Aging Research Center

Topics mentioned on this page:
Longevity Genes, DNA